Analysts Set Bausch Health Companies Inc. (NYSE:BHC) Target Price at $7.33

Bausch Health Companies Inc. (NYSE:BHC) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.33.

Several research firms have weighed in on BHC. Piper Sandler downgraded shares of Bausch Health Companies from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $9.00 to $3.00 in a research report on Friday, August 2nd. Truist Financial cut their target price on Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Royal Bank of Canada lowered their price target on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research report on Friday, August 2nd. Jefferies Financial Group cut their price objective on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Wednesday, September 25th.

Bausch Health Companies Stock Up 2.1 %

Shares of BHC opened at $8.10 on Tuesday. The company has a 50 day moving average of $6.67 and a two-hundred day moving average of $7.23. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -6.53 and a beta of 0.77.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.33 billion. During the same period in the previous year, the business earned $0.81 EPS. On average, sell-side analysts expect that Bausch Health Companies will post 3.61 EPS for the current year.

Insider Transactions at Bausch Health Companies

In other news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the transaction, the executive vice president now directly owns 435,198 shares of the company’s stock, valued at $2,702,579.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.12% of the company’s stock.

Institutional Investors Weigh In On Bausch Health Companies

A number of institutional investors have recently modified their holdings of the business. Prudential PLC purchased a new position in Bausch Health Companies during the fourth quarter worth approximately $735,000. Redwood Investment Management LLC grew its stake in Bausch Health Companies by 3.7% in the 4th quarter. Redwood Investment Management LLC now owns 401,495 shares of the company’s stock valued at $3,220,000 after acquiring an additional 14,184 shares during the period. Vanguard Group Inc. increased its holdings in Bausch Health Companies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 11,599,131 shares of the company’s stock worth $93,025,000 after acquiring an additional 111,363 shares in the last quarter. Salem Investment Counselors Inc. acquired a new position in Bausch Health Companies during the first quarter worth $32,000. Finally, Range Financial Group LLC lifted its holdings in Bausch Health Companies by 9.3% during the first quarter. Range Financial Group LLC now owns 88,415 shares of the company’s stock valued at $938,000 after purchasing an additional 7,514 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.